[
  {
    "ts": null,
    "headline": "Novo Nordisk Rolls Out Wegovy's Weight Loss Pill in US",
    "summary": "Novo Nordisk (NVO) said Monday that its Wegovy pill, the first oral medicine for obesity in the US,",
    "url": "https://finnhub.io/api/news?id=3a2a42854be48f78573d8907b87d6d08f5f340c5ac179a85fa3ac80f9bf79ba1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767640152,
      "headline": "Novo Nordisk Rolls Out Wegovy's Weight Loss Pill in US",
      "id": 137997666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NVO) said Monday that its Wegovy pill, the first oral medicine for obesity in the US,",
      "url": "https://finnhub.io/api/news?id=3a2a42854be48f78573d8907b87d6d08f5f340c5ac179a85fa3ac80f9bf79ba1"
    }
  },
  {
    "ts": null,
    "headline": "Biotech and Pharma Stocks Tumble as Investors Race into Energy",
    "summary": "Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.",
    "url": "https://finnhub.io/api/news?id=28a81daf1c3ad74136be78f734ee45654c1db7bb4e799156d35e55a1db347bb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767639120,
      "headline": "Biotech and Pharma Stocks Tumble as Investors Race into Energy",
      "id": 137997667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.",
      "url": "https://finnhub.io/api/news?id=28a81daf1c3ad74136be78f734ee45654c1db7bb4e799156d35e55a1db347bb4"
    }
  },
  {
    "ts": null,
    "headline": "McKesson Builds Earnings Momentum on Specialty and Automation",
    "summary": "McKesson posts a strong fiscal second quarter, lifts full-year EPS outlook, and shows how specialty growth and automation are reshaping its earnings power.",
    "url": "https://finnhub.io/api/news?id=d7db59a54fd1023ff59f2e100cf7667f2659d4db5abe4e1bd78f8b908ba29221",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767638640,
      "headline": "McKesson Builds Earnings Momentum on Specialty and Automation",
      "id": 137997954,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "McKesson posts a strong fiscal second quarter, lifts full-year EPS outlook, and shows how specialty growth and automation are reshaping its earnings power.",
      "url": "https://finnhub.io/api/news?id=d7db59a54fd1023ff59f2e100cf7667f2659d4db5abe4e1bd78f8b908ba29221"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Lags In The Weight-Loss Pill War. But It Has A Plan.",
    "summary": "Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight-loss drugs. But Lilly has a rival drug in the pipeline.",
    "url": "https://finnhub.io/api/news?id=3c4da6cbb3c82254c3586017832f3276757dc3d1893f474d202254eb65b3eea4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767636441,
      "headline": "Eli Lilly Lags In The Weight-Loss Pill War. But It Has A Plan.",
      "id": 137993616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight-loss drugs. But Lilly has a rival drug in the pipeline.",
      "url": "https://finnhub.io/api/news?id=3c4da6cbb3c82254c3586017832f3276757dc3d1893f474d202254eb65b3eea4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Lags In The Weight Loss Pill War. But It Has A Plan.",
    "summary": "Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight loss drugs. But Lilly has a rival drug in the pipeline.",
    "url": "https://finnhub.io/api/news?id=0f2b1925ceb1579c156372d041658982f1caddb7fb06e83310d9a22feb6f1827",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767636441,
      "headline": "Eli Lilly Lags In The Weight Loss Pill War. But It Has A Plan.",
      "id": 137993269,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight loss drugs. But Lilly has a rival drug in the pipeline.",
      "url": "https://finnhub.io/api/news?id=0f2b1925ceb1579c156372d041658982f1caddb7fb06e83310d9a22feb6f1827"
    }
  },
  {
    "ts": null,
    "headline": "European Equities Mostly Higher in Monday Trading; Novo Nordisk Rolls Out Wegovy Pill in US",
    "summary": "European stock markets closed mostly higher in Monday trading with the Stoxx Europe adding 0.9%, Ger",
    "url": "https://finnhub.io/api/news?id=7c4dde94c620185b2ede65074b76437b77ae3c0aa773b5bb7893018ae69a0ea2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767632959,
      "headline": "European Equities Mostly Higher in Monday Trading; Novo Nordisk Rolls Out Wegovy Pill in US",
      "id": 137992489,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "European stock markets closed mostly higher in Monday trading with the Stoxx Europe adding 0.9%, Ger",
      "url": "https://finnhub.io/api/news?id=7c4dde94c620185b2ede65074b76437b77ae3c0aa773b5bb7893018ae69a0ea2"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Rises on Launch of Weight-Loss Pills",
    "summary": "Novo Nordisk’s shares rallied after the drugmaker said its new Wegovy weight-loss pill is now broadly available in the U.S., following regulatory approval last month.  The Wegovy product is the first GLP-1 pill approved specifically for weight loss.  It will tap into what analysts expect will be substantial demand from consumers seeking an alternative to the injections that have dominated the anti-obesity market to date.",
    "url": "https://finnhub.io/api/news?id=dffa7aade06eeb5490fe1e2917ff9d8e279e6822f7a378eb3abf08dad9ee2a31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767625045,
      "headline": "Novo Nordisk Stock Rises on Launch of Weight-Loss Pills",
      "id": 137991006,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Novo Nordisk’s shares rallied after the drugmaker said its new Wegovy weight-loss pill is now broadly available in the U.S., following regulatory approval last month.  The Wegovy product is the first GLP-1 pill approved specifically for weight loss.  It will tap into what analysts expect will be substantial demand from consumers seeking an alternative to the injections that have dominated the anti-obesity market to date.",
      "url": "https://finnhub.io/api/news?id=dffa7aade06eeb5490fe1e2917ff9d8e279e6822f7a378eb3abf08dad9ee2a31"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk’s Wegovy Pill Now Broadly Available Across U.S.",
    "summary": "Novo Nordisk’s Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish drugmaker said.",
    "url": "https://finnhub.io/api/news?id=61433101f8fa8bd08dee976022d0f31a87c11bcfbf256baecfae6f168bee88d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767620520,
      "headline": "Novo Nordisk’s Wegovy Pill Now Broadly Available Across U.S.",
      "id": 137991009,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Novo Nordisk’s Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish drugmaker said.",
      "url": "https://finnhub.io/api/news?id=61433101f8fa8bd08dee976022d0f31a87c11bcfbf256baecfae6f168bee88d0"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America",
    "summary": "Wegovy® pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a pill for the first time. This advancement opens new possibilities for the more than 100 million Americans living with obesity.2 Wegovy® pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep i",
    "url": "https://finnhub.io/api/news?id=55d21e127d264d62c57d70ed1c9424124d41ccd5002abb89d917edb7a9bd867e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767618000,
      "headline": "Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America",
      "id": 137991073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Wegovy® pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a pill for the first time. This advancement opens new possibilities for the more than 100 million Americans living with obesity.2 Wegovy® pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep i",
      "url": "https://finnhub.io/api/news?id=55d21e127d264d62c57d70ed1c9424124d41ccd5002abb89d917edb7a9bd867e"
    }
  },
  {
    "ts": null,
    "headline": "First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.",
    "summary": "The drug's cash prices are among the lowest on the market, ranging from $149 to $299 per month, depending on the dose.",
    "url": "https://finnhub.io/api/news?id=41d5018d51222f453ae6b6e610dcfa530288df891e6c290e9b55a713672adbc2",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767600007,
      "headline": "First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. ",
      "id": 137992675,
      "image": "https://image.cnbcfm.com/api/v1/image/108231180-17640121262025-11-24t185244z_352081195_rc263iank3kr_rtrmadp_0_novo-nordisk.jpeg?v=1765918401&w=1920&h=1080",
      "related": "CVS",
      "source": "CNBC",
      "summary": "The drug's cash prices are among the lowest on the market, ranging from $149 to $299 per month, depending on the dose. ",
      "url": "https://finnhub.io/api/news?id=41d5018d51222f453ae6b6e610dcfa530288df891e6c290e9b55a713672adbc2"
    }
  },
  {
    "ts": null,
    "headline": "3 Things To Consider In December 2025's Jobs Report",
    "summary": "December 2025 NFP may stay resilient despite ADP/Challenger signals; Fed remains data-dependent.",
    "url": "https://finnhub.io/api/news?id=c6a92032f5aa05d4a5f1c647dbcd435eddde2639ede5cf8b0b9c9b94d756f395",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767600000,
      "headline": "3 Things To Consider In December 2025's Jobs Report",
      "id": 137990103,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412955054/image_1412955054.jpg?io=getty-c-w1536",
      "related": "CVS",
      "source": "SeekingAlpha",
      "summary": "December 2025 NFP may stay resilient despite ADP/Challenger signals; Fed remains data-dependent.",
      "url": "https://finnhub.io/api/news?id=c6a92032f5aa05d4a5f1c647dbcd435eddde2639ede5cf8b0b9c9b94d756f395"
    }
  }
]